Quarterly report pursuant to Section 13 or 15(d)

NOTES PAYABLE (Details 1)

v3.21.2
NOTES PAYABLE (Details 1)
$ / shares in Units, $ in Thousands
9 Months Ended 12 Months Ended
Sep. 30, 2020
USD ($)
Equity_Instrument
$ / shares
Dec. 31, 2019
USD ($)
Equity_Instrument
$ / shares
Sep. 22, 2020
Debt Instrument [Line Items]      
Interest rate     2.10%
Conversion Price | $ / shares $ 10.00    
Principal Outstanding $ 17,473 $ 17,142  
Discount Amount 2,491 3,190  
Carrying Amount $ 14,982 $ 13,952  
Shares Underlying Notes | Equity_Instrument 4,704,623 1,444,291  
2019 Convertible Debentures [Member]      
Debt Instrument [Line Items]      
Interest rate 10.00% 10.00%  
Term of Notes 18 months 18 months  
Principal Outstanding $ 8,700 $ 10,200  
Discount Amount 2,491 3,185  
Carrying Amount $ 6,209 $ 7,015  
Shares Underlying Notes | Equity_Instrument 4,387,986 1,080,415  
2019 Convertible Debentures [Member] | Minimum [Member]      
Debt Instrument [Line Items]      
Conversion Price | $ / shares [1] $ 2.00 $ 2.00  
2019 Convertible Debentures [Member] | Maximum [Member]      
Debt Instrument [Line Items]      
Conversion Price | $ / shares [1] $ 9.52 $ 9.52  
Convertible Debentures [Member]      
Debt Instrument [Line Items]      
Principal Outstanding $ 8,700 $ 10,200  
Discount Amount 2,491 3,185  
Carrying Amount $ 6,209 $ 7,015  
Shares Underlying Notes | Equity_Instrument 4,387,986 1,080,415  
Principal Outstanding, Current $ 8,700 $ 10,200  
Discount Amount, Current 2,491 3,185  
Convertible Debentures, Current $ 6,209 $ 7,015  
Shares Underlying Notes, Current | Equity_Instrument 4,387,986 1,080,415  
[1] These debentures are convertible into Emmaus Life Sciences, Inc. shares.